Related Experiment Video
Updated: May 31, 2026

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
Published on: May 12, 2023
Neutropenia in infants with hemolytic disease of the newborn
Esther Blanco1, Donna L Johnston
1Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
Background:
This study examined the incidence, outcome and risk factors of neutropenia in infants with hemolytic disease of the newborn (HDN).
Methods:
A retrospective chart review was performed on infants with HDN.
Results:
Of 69 evaluable infants, 45% developed neutropenia. Only one infectious complication was recorded. In most instances the neutropenia resolved spontaneously, but in seven infants it persisted for a median of 397 days. Males were at higher risk for developing neutropenia, but severity of HDN, antibody specificity, or therapy were not significant risk factors.
Conclusions:
Neutropenia is a common feature of HDN, regardless of severity of disease, treatment received, or antibody specificity.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Distribution
Rh Blood Group
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Drug Dosing: Infants and Children

